Mirion’s Strategic Pivot: Following the Nuclear Renaissance to Brussels

BRUSSELS – September 28, 2026 — For four decades, the epicenter of commercial radiation safety gathered on American soil. But as global capital continues its aggressive rotation away from speculative technology and toward hard-asset infrastructure, the compass has emphatically shifted. Mirion Technologies, the Atlanta-based heavyweight in radiation safety and measurement, has announced that its inaugural regional summit—Mirion Connect 2026 EMEA/APAC—will take place in Brussels, Belgium, from September 29 to October 1.

To the untrained eye, a change in conference venue might seem like a mere logistical footnote. However, for those of us tracking the intersection of corporate performance and market sentiment, this geographic expansion is a glaring leading indicator. It represents a calculated deployment of customer acquisition capital, precisely mirroring the explosive resurgence of European nuclear power and the continent's burgeoning dominance in radiopharmaceutical manufacturing.

As investors increasingly seek refuge from "AI fatigue" by hunting for high-moat, regulatory-driven industrial growth, understanding the "why behind the buy" in the radiation safety sector has never been more critical. Mirion is not simply hosting an event; it is mobilizing its commercial ecosystem to secure long-term engineering, retrofit, and compliance contracts in markets that now account for half of its global revenue.

Following the Capital Across the Atlantic

To understand the strategic gravity of the Brussels expansion, one must first look at the underlying revenue mechanics. While Mirion has historically centralized its flagship customer engagement in the United States, the reality of its balance sheet tells a decidedly international story. According to recent financial disclosures, a full 50 percent of the company’s global revenue is now generated outside of North America, with Europe contributing approximately 33 percent and the Asia-Pacific region adding another 17 percent.

Hosting Mirion Connect exclusively in the U.S. had created a structural friction point, distancing the company from half of its installed base and a massive pool of regional procurement decision-makers. Bringing the conference to Europe aligns the firm's engagement strategy directly with its international revenue profile and its ambitious full-year 2026 trajectory, which targets total annual revenue guidance of up to $1.13 billion.

“This inaugural Mirion Connect EMEA/APAC event reflects our commitment to building closer, more direct relationships with the global radiation safety community,” said Loïc Eloy, President, Nuclear & Safety Group at Mirion.

This commitment is backed by undeniable momentum. The company’s Nuclear and Safety Group, which drives roughly 40 percent of consolidated revenue, recently reported a 9.5 percent year-over-year jump, bolstered by organic growth in heavy nuclear power. By planting its flag in Brussels, the organization is positioning itself to capture the lucrative lifecycle monitoring contracts that inevitably follow major capital expenditures in energy infrastructure.

The SMR Catalyst and Europe’s Policy Reversal

Nowhere is that capital expenditure more evident than in the European energy sector, which is currently undergoing a profound policy reversal. After years of planned phaseouts, energy security concerns and aggressive decarbonization mandates have forced a continental pivot back to the atom.

Belgium itself serves as a perfect microcosm of this shift. In a landmark move, the Belgian Federal Parliament recently repealed its longstanding nuclear phaseout law, sanctioning the lifetime extension of critical reactors like Doel-4 and Tihange-3 through 2035, with negotiations ongoing for further extensions. The presence of Christophe Berbiers, Head of the CARE department at the Tihange Nuclear Power Station, on the Mirion Connect speaker roster highlights the operational realities facing European utilities today. Life extensions demand aggressive plant refurbishment, digital instrumentation upgrades, and continuous radiological condition monitoring—all core competencies of the event's host.

Furthermore, the continent is rapidly becoming a proving ground for Small Modular Reactors (SMRs). Driven by initiatives like the European SMR Industrial Alliance and Great British Nuclear, modular reactors are moving from concept to commercial deployment. Rolls-Royce SMR, represented at the conference by Lead Engineer Michael Hodgson, has already secured partnerships across the UK and the Czech Republic. For safety vendors, SMR instrumentation represents the "tip of the spear." Securing the initial sensor and monitoring contracts for these modular builds practically guarantees decades of recurring service and compliance revenue. It is a reality reflected in recent order books, where SMR-related bookings jumped to $39 million in a single year, surpassing the prior two years combined.

The Radiopharmaceutical Gold Rush

While the heavy industrial nuclear narrative dominates the headlines, an equally lucrative growth engine is quietly accelerating in the healthcare sector. Europe has firmly established itself as the global epicenter for the research, scale-up, and manufacturing of targeted radiopharmaceuticals, transforming clinical radiation monitoring from a niche hospital function into a high-growth industrial sector.

Belgium is affectionately known in biotech circles as the "Radioisotope Valley," supplying nearly a quarter of the world’s medical radioisotopes. The region is anchored by heavyweights like the Belgian Nuclear Research Centre and the National Institute for Radioelements. Now, a new wave of targeted alpha therapies is pushing the boundaries of oncology and safety engineering alike.

Targeted therapies utilizing alpha-emitters, such as Actinium-225, deliver immense energy over microscopic distances to destroy cancer cells. However, this same potency makes the synthesis and containment of these drugs exceptionally hazardous. Scaled commercial production demands specialized hot cells, remote manipulation, continuous aerosol air monitoring, and strict effluent controls.

This infrastructure bottleneck is precisely where advanced medical safety divisions step in. The conference will feature Philippe van Put, General Manager of Full Life Technologies, a company that recently obtained a critical permit to build a 4,000-square-meter automated GMP radiopharmaceutical manufacturing plant in Wallonia. As pharmaceutical giants pour billions into radioligand therapies, the specialized safety equipment required to manufacture these drugs has become an indispensable, high-margin enabler of the modern biotech supply chain.

Standardizing the Atom for a Complex Future

Ultimately, the strategic selection of Brussels as the host city transcends geographic convenience; it is a play for regulatory proximity. Situated mere miles from the regulatory seat of the European Atomic Energy Community (Euratom) and the European Commission’s Directorate-General for Energy, the venue places industry leaders at the very nexus of global nuclear policymaking.

As the industry races to deploy next-generation reactors and novel medical isotopes, the primary threat to commercialization is no longer technological—it is regulatory divergence. A fragmented landscape of national safety standards could cripple the supply chain efficiencies promised by SMRs and cross-border medical distribution.

By convening voices like Jonathan Burnett from the International Atomic Energy Agency (IAEA) alongside national utility operators and defense contractors, the summit aims to address this friction head-on. The goal is to harmonize environmental baseline testing, nuclear safeguards verification, and analytical protocols across diverse member states.

For market observers, the takeaway is clear. The companies that facilitate this cross-border standardization—while simultaneously supplying the proprietary hardware and software required to meet those standards—are building an unassailable competitive moat. As capital continues to flow into the European and Asian nuclear renaissance, the true beneficiaries may not just be the reactor builders or the drug developers, but the vital safety sentinels operating quietly in the background.